Excited to share my work for the last year on Protein Methyltransferase 5 (PRMT5), an emerging target for pancreatic cancer with its unique mechanisms of action (see Figures 1 & 2 in the article) with proven safety in phase I trials #PRMT5

This is promising with larger proportion of KRAS G12D than G12C we finally have something that leads to better PFS. The question is whether pan-KRAS inhibitor would be better and to ask the difficult question of how KRAS makes PDAC more aggressive

MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: 16%, MPR: 26%, any: 87% 👉 OS: HR: 0.78; 36-mo OS: 68 vs 61% 🧐OS improved independent of TAP, better in responders > new SOC @myesmo

Treatment selection pressure meant that upon progression post Claudin 18.2 targeting ADC that 75% retained some lower expression of 25% or more but is this good enough for another ADC to work? More so it can be toxic is our patients for enough for more ADC?

FLOT/TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative GC/GEJ cancer @TheLancetOncol https://t.co/gYSgJ6XveQ 🔎 PRODIGE 51-FFCD-GASTFOX phs 3 trial 👉ORR 62 vs 53% 👉mPFS 7·59 vs 5·98 mo 👉mOS 15·08 vs 12·65 mo 🧐Intersting option for fit pts

Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III controlled trials European J Cancer https://t.co/Gk4jm3GH9R 👉4 trials: BILCAP, ASCOT, BCAT, PRODIGE-12 👉only ASCOT met 1° EP 🧐Not convincing, we need to do

Finding the Right Partner: Triplet Therapy for 1st line Biliary Tract Cancers @JCO https://t.co/fajDInXdQ1 👉 SWOG-1815 was 🚫 despite promising phs-2 data 👉 Is there still a role of triplet CTx in BTC? 👉 Downstaging, neoadjuvant? 🧐 Summary of recent trials, food for

🧬Cancer types and genes associated with germline mutations 👇 @ASCO @OncoAlert @JCOPO_ASCO #cancer #oncology #genetics #MedX

💚💚💚ALBERTA AGREES TO COVER PEMAZYRE FOR CHOLANGIOCARCINOMA 🙌🤝💪 #CCAHope #cholangiocarcinoma #Alberta #CancerTreatment #HealthcareVictory #AdvocacyWorks https://t.co/xBez2ds1kX

Yesterday marks a milestone for the last 4 years becoming a clinician scientist and the fruit of my labour hopefully build towards a novel approach in targeting pancreatic cancer. I look forward to participate in recruiting patients to this treatment in the next few months!

‘A crime against cancer knowledge’: World-class Victorian research suffers major budget blow. New from @aishamae and I

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma https://t.co/XOl4P87rFd via @YahooFinance

For those interested to hear about the heavy science behind emerging treatment in clinical trial for pancreatic cancer … this is my answer… my hope for pancreatic cancer. Very cool biology but gives me a headache how amazing complicated it is….

The next generation of cancer drugs … precision guided bomb against her2 expression and it only requires some expression, not amplified expression. Bystander effect for once is not friendly fire but our friend.

#Pancare #DareToHope

Daring to hope for a pancreatic cancer advance, @MichaelKuanChi1 will today be announced as recipient of the Paul Dear Postdoctoral Fellowship - at the #aflhawkscats "Dare to Hope" match. Legacy of the late Hawthorn great Paul Dear. More: https://t.co/ZGlSJiIWoO

Proud to be part of the effort in our fight against pancreatic cancer. RNA biology may be the key to pancreatic cancer similar to what immunotherapy is to melanoma

What an amazing philanthropic effort… a figure we can’t even dream of.

An impressive 55 @PeterMacCC researchers have been named in the top 2% of most-cited scientists in the world based on a recently updated study published by @Stanford. The top two per cent includes the top 100,000 most cited scientists! Congratulations. 🥂 https://t.co/YqBhmAW8bd

Secondly the help of AI may be overstated as radiology report in China often subpar compared to report we receive in Australia. Moreover the false positive rate is concerning as EUS is not as benign as colonoscopy in false positive iFOBT.

Interesting work that non contrast CT can lead to more accurate diagnosis than contrast CT when radiomics traditionally has ROC 0.75-0.9 and this is at least 0.85. The significance for China is they do a lot of non contrast CT that we don’t see in the West